Telix Pharmaceuticals (TLX) Retained Earnings (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Retained Earnings for 3 consecutive years, with -$154.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Retained Earnings fell 10.96% year-over-year to -$154.5 million; the TTM figure through Dec 2025 stood at -$154.5 million (down 10.96% YoY), while the FY2025 annual figure was -$154.5 million, down 1.06% from the prior year.
• Retained Earnings fell to -$154.5 million in Q4 2025 per TLX's latest filing, from -$139.3 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$139.3 million in Q4 2024 and bottomed at -$171.6 million in Q4 2023.
• Historically, Retained Earnings has averaged -$155.1 million across 3 years, with a median of -$154.5 million in 2025.
• Annual changes were most pronounced in 2024 — Retained Earnings gained 18.86% — and 2025, when it dropped 10.96%.
• Telix Pharmaceuticals' Retained Earnings stood at -$171.6 million in 2023, then increased by 18.86% to -$139.3 million in 2024, then dropped by 10.96% to -$154.5 million in 2025.
• Business Quant data shows TLX's Retained Earnings at -$154.5 million in Q4 2025, -$139.3 million in Q4 2024, and -$171.6 million in Q4 2023.